Please login to the form below

Not currently logged in

Ipsen’s chief scientific officer steps down

Dr Claude Bertrand will be replaced ad interim by Alexandre Lebeaut

Ipsen Dr Claude BertrandIpsen's executive vice president of research and development and chief scientific officer Dr Claude Bertrand has stepped down from his post.

He will be replaced by Dr Alexandre Lebeaut as interim head of research and development while the firm searches for a permanent successor.

Dr Bertrand joined the French pharmaceutical firm in 2009, having moved from AstraZeneca where he most recently served as global vice president for launched and established brands.

Prior to this, Dr Bertrand held director-level and senior research positions at Novartis, Pfizer and Roche.

David Meek, chief executive officer of Ipsen, said: “On behalf of the company, I would like to thank Dr Bertrand for his significant contribution to leading the R&D organization during the past seven years.

“We wish him well as he moves on to pursue a new opportunity.”

He added: “We are fortunate to have an experienced and successful R&D leader like Dr Lebeaut to step up and lead the R&D team.”

12th January 2017

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...